Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$8.0B
64M shares
52-week range
$103.23 – $164.28
37% from low
Sector
PLASTICS PRODUCTS, NEC
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.76B | $2.86B | $2.93B | $3.23B | $3.32B | $3.49B | $3.58B | $3.78B |
| Cost of revenue | $1.81B | $1.82B | $1.84B | $2.07B | $2.16B | $2.22B | $2.23B | $2.66B |
| Gross profit | $951.8M | $1.04B | $1.09B | $1.16B | $1.16B | $1.26B | $1.36B | $1.12B |
| Gross margin | 34.4% | 36.4% | 37.1% | 35.8% | 35.0% | 36.2% | 37.8% | 29.6% |
| R&D | $75.3M | $82.8M | $92.5M | $99.8M | $0 | $0 | $0 | $105.1M |
| Operating income | $286.3M | $371.7M | $339.5M | $347.3M | $379.3M | $404.0M | $496.5M | $512.3M |
| EBITDA | $475.6M | $572.1M | $556.2M | $586.8M | $609.4M | $663.8M | $777.4M | $831.5M |
| Net income | $194.7M | $242.2M | $214.0M | $244.1M | $239.3M | $284.5M | $374.5M | $392.8M |
| Net margin | 7.0% | 8.5% | 7.3% | 7.6% | 7.2% | 8.2% | 10.5% | 10.4% |
| EPS (diluted) | 3.00 | 3.66 | 3.21 | 3.60 | 3.59 | 4.25 | 5.53 | 5.88 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4.0B | $5.51 | $5.32–$5.69 | 5 |
| 2027 | $4.2B | $6.36 | $5.90–$6.69 | 6 |
| 2028 | $4.4B | $7.08 | $6.72–$7.43 | 2 |
Forward consensus · source: Financial Modeling Prep
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
www.aptar.comNo one on the platform currently holds ATR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 172,800 | $21.8M |
| Bridgewater Associatesas of 2025-09-30 | 18,568 | $2.5M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-06 | $0.4800 | 2026-05-27 |
| 2026-02-04 | $0.4800 | 2026-02-25 |
| 2025-10-23 | $0.4800 | 2025-11-13 |
| 2025-07-24 | $0.4500 | 2025-08-14 |
| 2025-05-01 | $0.4500 | 2025-05-22 |
| 2025-02-05 | $0.4500 | 2025-02-26 |
| 2024-10-24 | $0.4500 | 2024-11-14 |
| 2024-07-25 | $0.4500 | 2024-08-15 |
| 2024-04-24 | $0.4100 | 2024-05-16 |
| 2024-01-31 | $0.4100 | 2024-02-22 |
No one on the platform has traded ATR yet.
| $9.3B |
| — |
| HSICHenry Schein, Inc. | $83.72 | -0.67% | $9.5B | — |
| MASIMasimo Corporation | $179.95 | +0.00% | $9.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-10-25 |
| $0.4100 |
| 2023-11-16 |
| 2023-07-26 | $0.4100 | 2023-08-17 |
| Execution date | Ratio |
|---|---|
| 2007-05-10 | 2-for-1 |
Trading at 22.9× earnings vs its 28.2× historical median P/E.
Fair value ≈ $154.54 · price $125.66 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Wall St is expecting 1.36 EPS for $ATR Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/atr?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗Wall St is expecting 1.36 EPS for $ATR Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/atr?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗https://marketbeat.com/a/8644542/ $ATR AptarGroup Sets CEO Succession as 2025 Sales Rise and Shareholders Back Ballot
View on StockTwits ↗$ATR Markets are being overly pessimistic. New CEO Gael Toya (sp?) led Pharma's growth under Tanda, and his leadership is exactly what the underperforming Beauty and Closures segments need here. Not sure what the exact business case is, but technically speaking the stock appears to be in a long term ascending channel, and the next peak wants to be around $200 in a couple years.
View on StockTwits ↗$ATR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $1.13 down -5.04% YoY • Reported revenue of $982.87M up 10.77% YoY • Aptar currently expects adjusted earnings per share for the second quarter of 2026 to range from $1.32 to $1.40, assuming an effective tax rate of 22.5% to 24.5%.
View on StockTwits ↗Wall St is expecting 1.15 EPS for $ATR Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/atr?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗Wall St is expecting 1.15 EPS for $ATR Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/atr?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗$ATR Opportunity Wells Fargo raises target price to $144 from $133 Wells Fargo raises to overweight from equal weight
View on StockTwits ↗$ATR Share Price: $145.73 Contract Selected: Aug 21, 2026 $145 Calls Buy Zone: $1.32 – $1.63 Target Zone: $2.15 – $2.63 Potential Upside: 54% ROI Time to Expiration: 178 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ATR Share Price: $135.46 Contract Selected: Aug 21, 2026 $135 Calls Buy Zone: $8.42 – $10.40 Target Zone: $15.99 – $19.55 Potential Upside: 79% ROI Time to Expiration: 192 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ATR - AptarGroup Inc. Common Stock - 10K - Updated Risk Factors ATR dropped its warning about share price pressure from large non-board institutional holders, slightly easing overhang concerns but leaving other 10-K risks intact. #ConsumerGoods #MarketOverhang #RegulatoryFiling #SharePriceRisk #InstitutionalInvestors 🟢 Added 🟠 Removed https://d-risk.ai/ATR/10-K/2026-02-06
View on StockTwits ↗$ATR is a diversified industrial with a strong filtration business; its aftermarket exposure provides resilience, but original equipment orders are softening.
View on StockTwits ↗$ATR Current Stock Price: $121.98 Contracts to trade: $120 ATR Jan 16 2026 Call Entry: $2.35 Exit: $2.94 ROI: 25% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$MIST $2.06 bid. Holding long position at a loss. UPDATE: Aptar Group, Inc. (NYSE: $ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the mechanism for delivering the newly approved CARDAMYST™ (etripamil) Nasal Spray. CARDAMYST received approval by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The novel treatment was developed by Milestone® Pharmaceuticals Inc. (Nasdaq: $MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. This marks Aptar’s first combination of dual Bidose delivery systems housed in a consumer-friendly protective two-pack container. ^^ An estimated two million people in the United States are currently diagnosed with PSVT, a type of arrhythmia or abnormal heart rhythm. PSVT is characterized by episodes of sudden onset rapid heartbeats often exceeding 150 to 200 beats per minute, resulting in an estimated 140,000 to 525,000 Emergency Department visits and 40,000 to 120,000 inpatient hospitalizations in the U.S. each year1. Integrated Bidose Device Container Closure System Ensures Reliable Drug Access CARDAMYST is easy to use and is small enough to be conveniently carried by patients for use as directed. Aptar CSP Technologies collaborated with Milestone Pharmaceuticals to develop a custom-designed, patient-friendly polypropylene container closure system with a fully integrated cap for CARDAMYST. This protective dual-container system is designed to securely house two Bidose delivery mechanisms, with features intended to prevent accidental activation or dropping from the container and help promote reliability at the moment of need. Gael Touya, President of Aptar Pharma, said, "This approval underscores the broadening of Aptar’s drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery. We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area." Alex Theodorakis, President, Aptar Pharma Prescription, added, "After years of close collaboration with Milestone, this successful outcome proves again our capability to support customers globally to develop and launch complex treatments with easy-to-use and reliable systems." ^^ "Aptar has been an essential partner in developing and delivering a novel treatment for PSVT that fills a serious unmet need. We are proud to partner with a company that shares our commitment to innovation and quality and look forward to working together to provide CARDAMYST to patients," said Joseph Oliveto, President and CEO, Milestone Pharmaceuticals.
$ATR's Bidose Nasal System Delivers $MIST's CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT) https://www.businesswire.com/news/home/20251217190273/en/Aptars-Bidose-Nasal-System-Delivers-CARDAMYST-etripamil-the-First-and-Only-Self-Administered-FDA-Approved-Nasal-Spray-for-Paroxysmal-Supraventricular-Tachycardia-PSVT
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.